Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Sandra Philipp
Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis
JAMA Dermatology
Dermatology
Medicine
Related publications
Efficacy and Safety Observed During 24 Weeks of Efalizumab Therapy in Patients With Moderate to Severe Plaque Psoriasis
Archives of Dermatology
Costs of Treatment in Patients With Moderate to Severe Plaque Psoriasis
Archives of Dermatology
Risankizumab vs. Ustekinumab for Plaque Psoriasis
British Journal of Dermatology
Dermatology
Medicine
Safety, Efficacy, and Drug Survival of Biologics and Biosimilars for Moderate-To-Severe Plaque Psoriasis
British Journal of Dermatology
Dermatology
Medicine
Safety and Efficacy of Guselkumab in Japanese Patients With Moderate-To-Severe Plaque Psoriasis: A Randomised, Placebo-Controlled, Ascending Dose Study
British Journal of Dermatology
Dermatology
Medicine
Ixekizumab Efficacy and Safety in Moderate-To-Severe Genital Psoriasis
British Journal of Dermatology
Dermatology
Medicine
Randomized, Controlled Study of Bleselumab (ASKP1240) Pharmacokinetics and Safety in Patients With Moderate-To-Severe Plaque Psoriasis
Biopharmaceutics and Drug Disposition
Medicine
Pharmacology
Pharmaceutical Science
Population Pharmacokinetics of Brodalumab in Patients With Moderate to Severe Plaque Psoriasis
Basic and Clinical Pharmacology and Toxicology
Medicine
Toxicology
Pharmacology
Lack of Effect of 12-Week Treatment With Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients With Moderate to Severe Chronic Plaque Psoriasis
Clinical Pharmacokinetics
Pharmacology